CN116103339A - Kit and application thereof in construction of pig nuclear transfer donor cells of COL2A1 gene mutation type II collagen disease model - Google Patents
Kit and application thereof in construction of pig nuclear transfer donor cells of COL2A1 gene mutation type II collagen disease model Download PDFInfo
- Publication number
- CN116103339A CN116103339A CN202211031148.2A CN202211031148A CN116103339A CN 116103339 A CN116103339 A CN 116103339A CN 202211031148 A CN202211031148 A CN 202211031148A CN 116103339 A CN116103339 A CN 116103339A
- Authority
- CN
- China
- Prior art keywords
- col2a1
- protein
- type
- model
- grna3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000027932 Collagen disease Diseases 0.000 title claims abstract description 68
- 108010041390 Collagen Type II Proteins 0.000 title claims abstract description 44
- 102000000503 Collagen Type II Human genes 0.000 title claims abstract description 44
- 101150082216 COL2A1 gene Proteins 0.000 title abstract description 27
- 238000012546 transfer Methods 0.000 title abstract description 7
- 206010064571 Gene mutation Diseases 0.000 title abstract description 6
- 238000010276 construction Methods 0.000 title description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 170
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 156
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- 210000000056 organ Anatomy 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 14
- 238000013334 tissue model Methods 0.000 claims abstract description 10
- 230000008506 pathogenesis Effects 0.000 claims abstract description 6
- 239000002773 nucleotide Substances 0.000 claims description 69
- 125000003729 nucleotide group Chemical group 0.000 claims description 69
- 239000013612 plasmid Substances 0.000 claims description 62
- 108091033409 CRISPR Proteins 0.000 claims description 38
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims description 24
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 20
- 108010013369 Enteropeptidase Proteins 0.000 claims description 19
- 108020001507 fusion proteins Proteins 0.000 claims description 18
- 102000037865 fusion proteins Human genes 0.000 claims description 18
- 102100029727 Enteropeptidase Human genes 0.000 claims description 16
- 241000894006 Bacteria Species 0.000 claims description 15
- 238000003776 cleavage reaction Methods 0.000 claims description 13
- 230000007017 scission Effects 0.000 claims description 13
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 12
- 241001052560 Thallis Species 0.000 claims description 12
- 238000000746 purification Methods 0.000 claims description 11
- 238000001042 affinity chromatography Methods 0.000 claims description 9
- 239000012460 protein solution Substances 0.000 claims description 9
- 108091005804 Peptidases Proteins 0.000 claims description 8
- 239000004365 Protease Substances 0.000 claims description 8
- 238000011144 upstream manufacturing Methods 0.000 claims description 8
- 108010006519 Molecular Chaperones Proteins 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 6
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 6
- 102000005431 Molecular Chaperones Human genes 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 238000011156 evaluation Methods 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 235000019750 Crude protein Nutrition 0.000 claims description 4
- 101150038500 cas9 gene Proteins 0.000 claims description 4
- 230000006698 induction Effects 0.000 claims description 4
- 230000030648 nucleus localization Effects 0.000 claims description 4
- 239000011347 resin Substances 0.000 claims description 4
- 229920005989 resin Polymers 0.000 claims description 4
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 claims description 3
- 102000007999 Nuclear Proteins Human genes 0.000 claims description 3
- 108010089610 Nuclear Proteins Proteins 0.000 claims description 3
- 238000002659 cell therapy Methods 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 230000000857 drug effect Effects 0.000 claims description 3
- 238000001415 gene therapy Methods 0.000 claims description 3
- 238000009630 liquid culture Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 230000035772 mutation Effects 0.000 abstract description 25
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 description 79
- 241000282898 Sus scrofa Species 0.000 description 56
- 210000002950 fibroblast Anatomy 0.000 description 46
- 238000013518 transcription Methods 0.000 description 29
- 230000035897 transcription Effects 0.000 description 29
- 238000012163 sequencing technique Methods 0.000 description 26
- 239000000243 solution Substances 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 22
- 108020005004 Guide RNA Proteins 0.000 description 20
- 238000010362 genome editing Methods 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 18
- 238000001890 transfection Methods 0.000 description 17
- 241000282887 Suidae Species 0.000 description 16
- 108091026890 Coding region Proteins 0.000 description 14
- 102000053602 DNA Human genes 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 10
- 238000012408 PCR amplification Methods 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 229910052754 neon Inorganic materials 0.000 description 10
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 10
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 9
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 9
- 238000012217 deletion Methods 0.000 description 9
- 230000037430 deletion Effects 0.000 description 9
- 238000001962 electrophoresis Methods 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 238000012224 gene deletion Methods 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 108090000631 Trypsin Proteins 0.000 description 7
- 102000004142 Trypsin Human genes 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000012588 trypsin Substances 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 6
- 102000035195 Peptidases Human genes 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 238000005520 cutting process Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 235000019419 proteases Nutrition 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 5
- 241000288906 Primates Species 0.000 description 5
- 238000000246 agarose gel electrophoresis Methods 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 238000012761 co-transfection Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000000108 ultra-filtration Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 101001012262 Bos taurus Enteropeptidase Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000011536 extraction buffer Substances 0.000 description 4
- 238000003209 gene knockout Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 101150009573 phoA gene Proteins 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 238000010354 CRISPR gene editing Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000002933 Thioredoxin Human genes 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 244000309715 mini pig Species 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000010374 somatic cell nuclear transfer Methods 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 108060008226 thioredoxin Proteins 0.000 description 3
- 229940094937 thioredoxin Drugs 0.000 description 3
- 108700010070 Codon Usage Proteins 0.000 description 2
- 108010074860 Factor Xa Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108010076818 TEV protease Proteins 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 108010087967 type I signal peptidase Proteins 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100029136 Collagen alpha-1(II) chain Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 101100118093 Drosophila melanogaster eEF1alpha2 gene Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000701867 Enterobacteria phage T7 Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 101000771163 Homo sapiens Collagen alpha-1(II) chain Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102000002488 Nucleoplasmin Human genes 0.000 description 1
- 206010057178 Osteoarthropathies Diseases 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 108010090127 Periplasmic Proteins Proteins 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 101000582398 Staphylococcus aureus Replication initiation protein Proteins 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 101150110111 Ttn gene Proteins 0.000 description 1
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 210000003035 hyaline cartilage Anatomy 0.000 description 1
- -1 i.e. Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 108060005597 nucleoplasmin Proteins 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 108010060175 trypsinogen activation peptide Proteins 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
- C12N15/877—Techniques for producing new mammalian cloned embryos
- C12N15/8778—Swine embryos
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0656—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/108—Swine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Rheumatology (AREA)
- Pathology (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Husbandry (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biodiversity & Conservation Biology (AREA)
- Diabetes (AREA)
Abstract
The invention discloses a kit and application thereof in constructing a model pig nuclear transfer donor cell of a COL2A1 gene mutation type II collagen disease. The present invention provides SEQ ID NO:16, COL2A1-gRNA3, SEQ ID NO:17 and NCN protein of COL2A1-gRNA4 in the preparation of the kit. The invention also provides a method for preparing the recombinant pig cell: and co-transfecting the COL2A1-gRNA3, the COL2A1-gRNA4 and the NCN protein into the pig cells to obtain the recombinant pig cells. The recombinant porcine cell is a recombinant porcine cell with mutation of COL2A1 gene. The kit has the following purposes: preparing recombinant pig cells; preparing a model pig of type II collagen diseases; preparing a type II collagenosis cell model, a type II collagenosis tissue model or a type II collagenosis organ model. The invention has great application value for researching and developing type II collagen diseases and revealing pathogenesis of the diseases.
Description
Technical Field
The invention belongs to the technical field of biology, in particular to the technical field of gene editing, and more particularly relates to a kit and application thereof in constructing a model pig nuclear transfer donor cell of COL2A1 gene mutation II type collagen disease.
Background
Collagen is one of the largest protein types in humans, and type ii collagen is an important protein constituting articular cartilage and hyaline cartilage. The COL2A1 gene encodes a type II collagen precursor, so that mutation of the COL2A1 gene results in a change in the structure of type II collagen, which in turn results in a type II collagen disease (also known as type II collagen disease). Type II collagen disease is an autosomal dominant inherited disease, and the main symptoms of patients include cartilage dysplasia and osteoarthropathy everywhere.
COL2A1 gene codes alpha chain of II type collagen precursor protein, 3 identical alpha chains are folded mutually to form precursor protein homotrimer, and the homotrimer is crosslinked to form mature II type collagen protein. There is a special triple helix region in the alpha chain, which is characterized by repeated Gly-X-Y sequences (Gly is glycine, X and Y are other amino acids), and the triple helix structure plays an important role in the stability of collagen molecules.
Research on the occurrence and development mechanism of type II collagen diseases and research on corresponding medicaments are all required to be carried out on the basis of animal models, and the animal models which are commonly used at present are mouse models, however, mice have huge differences from human beings in aspects of body type, organ size, physiology, pathology and the like, and normal physiological and pathological states of human beings cannot be truly simulated. As a large animal, the pig has the size and physiological functions similar to those of human beings, is easy to breed and raise in a large scale, has lower requirements on ethical morals, animal protection and the like, and is an ideal human disease model animal.
Gene editing is a biotechnology that has been greatly developed in recent years, and includes editing technologies from gene editing based on homologous recombination to ZFN, TALEN, CRISPR/Cas9 based on nucleases, and the CRISPR/Cas9 technology is currently the most advanced gene editing technology. Currently, gene editing techniques are increasingly applied to the production of animal models.
Disclosure of Invention
The invention aims to provide a kit and application thereof in constructing a model pig nuclear transfer donor cell of a COL2A1 gene mutation type II collagenosis.
The invention provides application of COL2A1-gRNA3, COL2A1-gRNA4 and NCN proteins in preparation of a kit.
The invention also provides application of COL2A1-gRNA3, COL2A1-gRNA4 and PRONCN proteins in preparation of a kit.
The invention also provides application of the COL2A1-gRNA3, the COL2A1-gRNA4 and the specific plasmid in preparation of a kit.
The invention provides a kit which comprises COL2A1-gRNA3, COL2A1-gRNA4 and NCN proteins.
The invention also provides a kit comprising COL2A1-gRNA3, COL2A1-gRNA4 and PRONCN proteins.
The invention also provides a kit comprising COL2A1-gRNA3, COL2A1-gRNA4 and specific plasmids.
Any of the above kits further comprises pig cells.
The use of any of the above kits is as follows (a) or (b) or (c): (a) preparing recombinant porcine cells; (b) preparing a model pig of type ii collagen disease; (c) Preparing a type II collagenosis cell model, a type II collagenosis tissue model or a type II collagenosis organ model.
The invention provides a method for preparing recombinant porcine cells, which comprises the following steps: and co-transfecting the COL2A1-gRNA3, the COL2A1-gRNA4 and the NCN protein into the pig cells to obtain the recombinant pig cells.
The cotransfection adopts a specific electric shock transfection mode.
The parameter settings for electric shock transfection can be specifically: 1450V, 10ms, 3pulse.
The cotransfection can be specifically performed by using a mammalian nuclear transfection kit (Neon kit, thermofiser) and a Neon TM transfection system electrotransfection apparatus.
The ratios of COL2A1-gRNA3, COL2A1-gRNA4 and NCN protein are as follows: 0.8-1.2 μg COL2A1-gRNA3:0.8-1.2 μg COL2A1-gRNA4:3-5 μg NCN protein.
The ratios of COL2A1-gRNA3, COL2A1-gRNA4 and NCN protein are as follows: 1 μg COL2A1-gRNA3:1 μg COL2A1-gRNA4:4 μg NCN protein.
The proportion of pig cells, COL2A1-gRNA3, COL2A1-gRNA4 and NCN protein is as follows: 10 ten thousand pig cells: 0.8-1.2 μg COL2A1-gRNA3:0.8-1.2 μg COL2A1-gRNA4:3-5 μg NCN protein.
The proportion of pig cells, COL2A1-gRNA3, COL2A1-gRNA4 and NCN protein is as follows: 10 ten thousand pig cells: 1 μg COL2A1-gRNA3:1 μg COL2A1-gRNA4:4 μg NCN protein.
Any one of the COL2A1-gRNA3 is sgRNA, and the target sequence binding region is shown in SEQ ID NO:16 from nucleotide 3 to nucleotide 22.
Specifically, COL2A1-gRNA3 is shown in SEQ ID NO: shown at 16.
Specifically, COL2A1-gRNA3 is shown in SEQ ID NO: shown at 12.
Any of the COL2A1-gRNA4 is sgRNA, and the target sequence binding region is shown in SEQ ID NO:17 from nucleotide 3 to nucleotide 22.
Specifically, COL2A1-gRNA4 is shown in SEQ ID NO: shown at 17.
Specifically, COL2A1-gRNA4 is shown in SEQ ID NO: shown at 13.
Any of the above NCN proteins is a Cas9 protein or a fusion protein with a Cas9 protein.
Specifically, the NCN protein is shown as SEQ ID NO: 3.
Any of the above-described porcine cells are porcine fibroblasts.
Any of the above described porcine cells are porcine primary fibroblasts.
Any of the above-described porcine cells are porcine primary fibroblasts obtained from a primary pig.
The preparation method of the NCN protein comprises the following steps:
(1) Introducing plasmid pKG-GE4 into escherichia coli BL21 (DE 3) to obtain recombinant bacteria;
(2) Culturing the recombinant bacteria at 30 ℃ by adopting a liquid culture medium, then adding IPTG, performing induction culture at 25 ℃, and then collecting thalli;
(3) Crushing the collected thalli, and collecting a crude protein solution;
(4) Purification of His-bearing proteins from the crude protein solution by affinity chromatography 6 A tagged fusion protein;
(5) By using a composition having His 6 Enterokinase cleavage of tag with His 6 Tagged fusion proteins are then removed with Ni-NTA resin to remove His 6 A tagged protein, resulting in a purified NCN protein;
plasmid pKG-GE4 has the sequence of SEQ ID NO:1 from nucleotide 5209 to nucleotide 9852.
The preparation method of the NCN protein specifically comprises the following steps:
(1) The plasmid pKG-GE4 was introduced into E.coli BL21 (DE 3) to obtain a recombinant strain.
(2) Inoculating the recombinant bacteria obtained in the step (1) to a liquid LB culture medium containing ampicillin, and carrying out shake culture;
(3) Inoculating the bacterial liquid obtained in the step (2) into a liquid LB culture medium, and culturing at 30 ℃ and 230rpm in a shaking way until the bacterial liquid reaches OD 600nm Value = 1.0, then IPTG was added to bring the concentration in the system to 0.5mM, then shaking culture was performed at 25 ℃, 230rpm for 12 hours, and then the cells were collected by centrifugation;
(4) Washing the thalli obtained in the step (3) with PBS buffer solution;
(5) Adding the thalli obtained in the step (4) into a crude extraction buffer solution, suspending the thalli, crushing the thalli, centrifugally collecting supernatant, filtering by adopting a filter membrane with the aperture of 0.22 mu m, and collecting filtrate;
(6) Purifying the His-bearing fraction from the filtrate obtained in step (5) by affinity chromatography 6 A tagged fusion protein (fusion protein shown in SEQ ID NO: 2);
(7) Taking the post-column solution collected in the step (6), concentrating the post-column solution by using an ultrafiltration tube, and diluting the post-column solution by using 25mM Tris-HCl (pH 8.0);
(8) Will have His 6 Adding the labeled recombinant bovine enterokinase into the solution obtained in the step (7), and performing enzyme digestion;
(9) Uniformly mixing the solution obtained in the step (8) with Ni-NTA resin, incubating, and centrifuging to collect supernatant;
(10) Concentrating the supernatant obtained in the step (9) by using an ultrafiltration tube, and then adding the concentrated supernatant into an enzyme stock solution to obtain the NCN protein solution.
Purifying the His-bearing fraction from the filtrate obtained in step (5) by affinity chromatography 6 The specific method of the fusion protein of the tag is as follows:
firstly, balancing a Ni-NTA agarose column (the flow rate is 1 ml/min) by adopting balancing liquid with 5 column volumes; then, 50ml of the filtrate obtained in the step (5) is loaded (the flow rate is 0.5-1 ml/min); the column was then washed with 5 column volumes of equilibration liquid (flow rate 1 ml/min); the column was then washed with 5 column volumes of buffer (flow rate 1 ml/min) to remove the contaminating proteins; then eluting with 10 column volumes of eluent at a flow rate of 0.5-1ml/min, and collecting the column-passing solution (90-100 ml).
Any of the above procn proteins comprises the following elements in order from upstream to downstream: signal peptide, chaperone protein, protein tag, protease cleavage site, nuclear localization signal, cas9 protein, nuclear localization signal.
The function of the signal peptide is to promote secretory expression of the protein. The signal peptide may be selected from the group consisting of an E.coli alkaline phosphatase (phoA) signal peptide, a Staphylococcus aureus protein A signal peptide, an E.coli outer membrane protein (ompa) signal peptide or a signal peptide of any other prokaryotic gene, preferably an alkaline phosphatase signal peptide (phoA signal peptide). The alkaline phosphatase signal peptide is used for guiding the secretion and expression of the target protein into the periplasmic cavity of the bacterium so as to be separated from the intracellular protein of the bacterium, and the target protein secreted into the periplasmic cavity of the bacterium is expressed in a soluble way and can be cracked by the signal peptidase in the periplasmic cavity of the bacterium.
The chaperone protein functions to increase the solubility of the protein. The chaperone may be any protein that aids in disulfide bond formation, preferably a thioredoxin (TrxA protein). Thioredoxin, which can serve as a molecular chaperone to help the co-expressed target protein (e.g., cas9 protein) form disulfide bonds, improving the stability of the protein, the correctness of folding, and increasing the solubility and activity of the target protein.
The function of the protein tag is for protein purification. The Tag may be a His Tag (His-Tag, his) 6 Protein tag), GST tag, flag tag, HA tag, c-Myc tag or any other protein tag, further preferably His tag. His tag can be combined with Ni column, and target protein can be purified by one-step Ni column affinity chromatography, so that the purification process of target protein can be greatly simplified.
The protease cleavage site functions to cleave off the nonfunctional segment after purification to release the native form of Cas9 protein. The protease may be selected from Enterokinase (Enterokinase), factor Xa (Factor Xa), thrombin (Thrombin), TEV protease (TEV protease), HRV 3C protease (HRV 3C protease), WELQut protease or any other endoprotease, further preferably Enterokinase. EK is enterokinase cleavage site, which is convenient for cutting fused TrxA-His segment by enterokinase to obtain the natural form Cas9 protein. After the commercial enterokinase enzyme digestion fusion protein with the His tag is used, the TrxA-His segment and the enterokinase with the His tag can be removed through one-time affinity chromatography, the Cas9 protein in a natural form is obtained, and the damage and the loss of the target protein caused by repeated purification and dialysis are avoided.
The nuclear localization signal may be any nuclear localization signal, preferably an SV40 nuclear localization signal and/or a nucleoplasmin nuclear localization signal. NLS is a nuclear localization signal, and an NLS site is designed at the N end and the C end of Cas9 respectively, so that Cas9 can enter the nucleus more effectively for gene editing.
The Cas9 protein may be saCas9 or spCas9, preferably spCas9 protein.
The PRONCN protein is specifically shown as SEQ ID NO: 2.
Any of the above specific plasmids comprises the following elements in order from upstream to downstream: promoters, operators, ribosome binding sites, genes encoding procn proteins, and terminators.
The promoter may specifically be a T7 promoter. The T7 promoter is a prokaryotic expression strong promoter and can efficiently drive the expression of exogenous genes.
The operon may specifically be the Lac operon. The Lac operon is a regulatory element for lactose induced expression, and can induce the expression of the target protein at low temperature after bacteria grow to a certain amount, thereby avoiding the influence of the premature expression of the target protein on the growth of host bacteria, and remarkably improving the solubility of the expressed target protein by the induced expression at low temperature.
The ribosome binding site is a ribosome binding site for protein translation, and is necessary for protein translation.
The terminator may specifically be a T7 terminator. The T7 terminator can effectively terminate gene transcription at the tail end of the target gene, and prevent other downstream sequences except the target gene from being transcribed and translated.
The codon of the spCas9 protein is optimized, so that the codon is completely adapted to the codon preference of the E.coli BL21 (DE 3) strain for efficiently expressing the E.coli selected in the application, and the expression level of the Cas9 protein is improved.
The T7 promoter is shown in SEQ ID NO:1 from nucleotide 5121 to 5139.
The Lac operon is shown in SEQ ID NO:1 from nucleotide 5140 to 5164.
Ribosome binding sites are shown in SEQ ID NO:1 from nucleotide 5178 to nucleotide 5201.
The coding sequence of the alkaline phosphatase signal peptide is shown in SEQ ID NO:1 from nucleotide 5209 to nucleotide 5271.
The coding sequence of the TrxA protein is shown as SEQ ID NO:1 from nucleotide 5272 to 5598.
The coding sequence of His-Tag is shown as SEQ ID NO:1 from nucleotide 5620 to nucleotide 5637.
The coding sequence of the enterokinase enzyme cutting site is shown as SEQ ID NO:1 from nucleotide 5638 to nucleotide 5652.
The coding sequence of the nuclear localization signal is shown as SEQ ID NO:1 from nucleotide 5656 to nucleotide 5670.
The encoding sequence of the spCas9 protein is shown as SEQ ID NO:1 from nucleotide 5701 to nucleotide 9801.
The coding sequence of the nuclear localization signal is shown as SEQ ID NO:1 from nucleotide 9802 to nucleotide 9849.
T7 terminator is shown in SEQ ID NO:1 from nucleotide 9902 to nucleotide 9949.
Specifically, the specific plasmid is plasmid pKG-GE4.
Plasmid pKG-GE4 has the sequence of SEQ ID NO:1 from nucleotide 5121 to 9949.
Specifically, any one of the plasmids pKG-GE4 is shown in SEQ ID NO: 1.
The invention also provides the recombinant pig cell prepared by any one of the methods.
The recombinant porcine cell is a recombinant porcine cell with mutation of COL2A1 gene.
The recombinant porcine cells can be specifically single-cell clones with the genotypes of heterozygous, double-allele same mutant or double-allele different mutant in table 1.
The invention also protects the application of the recombinant porcine cells in preparing a model pig with type II collagenosis.
And (3) taking the recombinant pig cells as nuclear transfer donor cells to clone somatic cells, so that cloned pigs, namely type II collagen disease model pigs, can be obtained.
The invention also protects the pig tissue of the model pig prepared by the recombinant pig cells, namely a type II collagen disease tissue model.
The invention also protects a pig organ of a model pig prepared by using the recombinant pig cell, namely a type II collagen disease organ model.
The invention also protects the pig cells of the model pig prepared by the recombinant pig cells, namely a type II collagen disease cell model.
The invention also protects the application of the recombinant pig cell, the type II collagen disease tissue model, the type II collagen disease organ model, the type II collagen disease cell model or the type II collagen disease model pig, which is (d 1) or (d 2) or (d 3) or (d 4):
(d1) Screening a medicament for treating type II collagen diseases;
(d2) Performing drug effect evaluation of the type II collagen disease drug;
(d3) Performing therapeutic effect evaluation of gene therapy and/or cell therapy of type II collagen diseases;
(d4) The pathogenesis of type II collagen diseases is studied.
Any of the above pigs may specifically be a from-river fragrant pig.
Any of the above pigs may be specifically a junior river-origin fragrant pig.
Any of the above pigs may specifically be Bama miniature pigs.
Any of the above pigs may specifically be primary Bama miniature pigs.
Any of the above collagen type II diseases is caused by mutation of COL2A1 gene.
Pig COL2A1 gene information: encoding type ii collagen α1 chain; chromosome 5; gene ID 397323,Sus scrofa.
The protein encoded by the porcine COL2A1 gene is shown as XP_020948270.1 (13-MAY-2017) in NCBI.
The protein encoded by the pig COL2A1 gene has the sequence shown in SEQ ID NO: 8.
The pig COL2A1 gene has SEQ ID NO: 9.
Any of the above mutations is a deletion and/or insertion and/or substitution of one or more nucleotides.
Any of the above mutations is a deletion of one or more nucleotides.
Any of the above mutations is an insertion of one or more nucleotides.
Any of the above mutations is a deletion or insertion of one or more nucleotides.
Compared with the prior art, the invention has at least the following beneficial effects:
(1) The subject (pig) of the invention has better applicability than other animals (rats, mice, primates).
Rodents such as rats and mice have great differences from humans in terms of body type, organ size, physiology, pathology and the like, and cannot truly simulate normal physiological and pathological states of humans. Studies have shown that more than 95% of drugs that are validated in mice are ineffective in human clinical trials. In the case of large animals, primates are animals with the closest relationship to humans, but are small in size, late in sexual maturity (mating begins at 6-7 years old), and single animals, the population expansion rate is extremely slow, and the raising cost is high. In addition, primate cloning is inefficient, difficult and costly.
The pig is an animal which has the closest relationship with human except primate, and has the similar body shape, weight, organ size and the like as human, and has the similar anatomical, physiological, immunological, nutritional metabolism, disease pathogenesis and the like as human. Meanwhile, the pigs are early in sexual maturity (4-6 months), have high fertility and have more piglets, and can form a larger group within 2-3 years. In addition, the cloning technology of pigs is very mature, and the cloning and feeding costs are much lower than those of primates. Pigs are thus very suitable animals as models of human diseases.
(2) The vector constructed by the invention uses a strong promoter T7-lac capable of efficiently expressing the target protein to express the target protein, and uses a signal peptide of bacterial periplasmic protein alkaline phosphatase (phoA) to guide the secretory expression of the target protein into a bacterial periplasmic cavity so as to separate from bacterial intracellular proteins, wherein the target protein secreted into the bacterial periplasmic cavity is expressed in a soluble way. Meanwhile, the fusion expression of the thioredoxin TrxA and the Cas9 protein is adopted, the TrxA can help the co-expressed target protein to form disulfide bonds, the stability and folding correctness of the protein are improved, and the solubility and activity of the target protein are increased. In order to facilitate purification of the target protein, a His tag is designed, and the target protein can be purified by one-step Ni column affinity chromatography, so that the purification process of the target protein is greatly simplified. Meanwhile, an enterokinase enzyme cutting site is designed behind the His tag, so that fused TrxA-His polypeptide fragments can be conveniently cut off, and the Cas9 protein in a natural form is obtained. After the fusion protein is digested by using the enterokinase with the His tag, the TrxA-His polypeptide fragment and the enterokinase with the His tag can be removed by one-time affinity chromatography to obtain the natural form of the Cas9 protein, thereby avoiding the damage and the loss of the target protein caused by multiple purification dialysis. Meanwhile, the N end and the C end of the Cas9 are respectively designed with an NLS site, so that the Cas9 can enter a cell nucleus more effectively for gene editing. In addition, the E.coli BL21 (DE 3) strain is selected as a target protein expression strain, and the strain can efficiently express and clone exogenous genes in an expression vector (such as pET-32 a) containing a phage T7 promoter. Meanwhile, the codon of the Cas9 protein is optimized, so that the codon is completely adapted to the codon preference of an expression strain, and the expression level of the target protein is improved. In addition, after bacteria grow to a certain quantity, the invention uses IPTG to induce the expression of the target protein at low temperature, thereby avoiding the influence of the premature expression of the target protein on the growth of host bacteria, and obviously improving the solubility of the expressed target protein by the induction expression at low temperature. Through the optimization design and experimental implementation, the activity of the obtained Cas9 protein is remarkably improved compared with that of commercial Cas9 protein.
(3) The gene editing is carried out by adopting the Cas9 high-efficiency protein combined in vitro transcribed gRNA constructed and expressed by the invention, and the optimal dosage proportion of Cas9 and gRNA is optimized, so that the finally obtained single cell cloning rate of the gene editing is as high as 97.1 percent, which is far higher than the conventional gene editing efficiency (10-30 percent).
(4) The target gene knockout monoclonal strain obtained by the invention is used for cloning somatic cell nuclear transfer animals, so that the cloned pig with the target gene knockout can be directly obtained, and the gene variation can be inherited stably.
The method of microinjection of gene editing material into fertilized ovum and embryo transplantation adopted in the mouse model production is not suitable for the production of large animal (such as pig) model with longer gestation period because the probability of directly obtaining the offspring of gene mutation is low, the hybrid breeding of the offspring is needed. Therefore, the method for editing primary cells in vitro, cutting Cas9 protein and double gRNA and screening positive editing single cell clones with high technical difficulty and high challenges is adopted, and corresponding disease model pigs are directly obtained through somatic cell nuclear transfer animal cloning technology in the later period, so that the model pig manufacturing period can be greatly shortened, and manpower, material resources and financial resources are saved.
The invention adopts CRISPR/Cas9 technology and double gRNA editing to knock out COL2A1 gene, simulates the genetic characteristics of type II collagenosis, obtains single cell clone of COL2A1 gene knockout, and lays a foundation for culturing type II collagenosis model pigs by somatic cell nuclear transfer animal cloning technology in the later period. The invention is helpful for researching and disclosing pathogenesis of type II collagen diseases caused by COL2A1 gene dysfunction, can also be used for researching drug screening, drug effect evaluation, gene therapy, cell therapy and the like, can provide effective experimental data for further clinical application, and further provides a powerful experimental means for successfully treating type II collagen diseases of human beings. The invention has great application value for researching and developing type II collagen diseases and revealing pathogenesis of the diseases.
Drawings
FIG. 1 shows the results of forward sequencing of the single cell clone numbered 33 with the wild type sequence.
FIG. 2 shows the results of reverse sequencing of the single cell clone No. 14 compared to the wild type sequence.
FIG. 3 shows the results of reverse sequencing of the single cell clone numbered 24 compared to the wild type sequence.
FIG. 4 shows the results of the forward sequencing of the single cell clone numbered 2 compared to the wild type sequence.
FIG. 5 is an electrophoretogram of example 2 using ear tissue extracted genome of swine designated BX4 as a template for PCR amplification using different primer pairs.
FIG. 6 is an electrophoretogram of PCR amplification using 10 pig genomic DNAs as templates and primer sets consisting of COL2A1-E27-JDF219 and COL2A1-E27-JDR660 in example 2.
FIG. 7 is a schematic diagram of the structure of plasmid pET-32 a.
FIG. 8 is a schematic diagram of the structure of plasmid pKG-GE 4.
FIG. 9 is an electrophoretogram of the optimization of the ratio of gRNA to NCN protein in example 4.
Fig. 10 is an electrophoretogram of the comparison of gene editing efficiency of NCN protein and commercial Cas9 protein in example 4.
Detailed Description
The following detailed description of the invention is provided in connection with the accompanying drawings that are presented to illustrate the invention and not to limit the scope thereof. The examples provided below are intended as guidelines for further modifications by one of ordinary skill in the art and are not to be construed as limiting the invention in any way.
The experimental methods in the following examples, unless otherwise specified, are conventional methods, and are carried out according to techniques or conditions described in the literature in the field or according to the product specifications. Materials, reagents and the like used in the examples described below are commercially available unless otherwise specified. The recombinant plasmids constructed in the examples were all subjected to sequencing verification. The commercial Cas9-A protein is a commercially available Cas9 protein with good effect. The commercial Cas9-B protein is a commercially available Cas9 protein with good effect. Complete culture solution (% by volume): 15% fetal bovine serum (Gibco) +83% DMEM Medium (Gibco) +1% Penicillin-Streptomycin (Gib) co) +1% HEPES (Solarbio). Cell culture conditions: 37 ℃,5% CO 2 、5%O 2 Is a constant temperature incubator.
The porcine primary fibroblasts used in examples 1 and 2 were prepared from primary Bama miniature pig ear tissue. The porcine primary fibroblasts employed in example 4 were prepared from a primary tissue of the Jiang Xiang pig ear. A method for preparing porcine primary fibroblasts from porcine ear tissue: (1) taking 0.5g of pig ear tissue, removing hair and bone tissue, soaking the pig ear tissue in 75% alcohol for 30-40s, washing the pig ear tissue with PBS buffer solution containing 5% (volume ratio) Penicillin-Streptomycin (Gibco) for 5 times, and washing the pig ear tissue with the PBS buffer solution for one time; (2) shearing the tissue with scissors, digesting with 5mL of 0.1% collagenase solution (Sigma) at 37 ℃ for 1h, centrifuging 500g for 5min, and discarding the supernatant; (3) the pellet was resuspended in 1mL of complete medium, then plated into a 10cm diameter cell culture dish containing 10mL of complete medium and capped with 0.2% gelatin (VWR), and cultured until the cells grew to about 60% of the bottom of the dish; (4) after step (3) is completed, cells are digested and harvested with trypsin and then resuspended in complete medium. For carrying out subsequent electrotransformation experiments.
Plasmid pKG-GE3 is a circular plasmid, as set forth in SEQ ID NO: 2. SEQ ID NO in patent application 202010084343.6: 2, nucleotide 395-680 constitutes CMV enhancer, nucleotide 682-890 constitutes EF1a promoter, nucleotide 986-1006 encodes Nuclear Localization Signal (NLS), nucleotide 1016-1036 encodes Nuclear Localization Signal (NLS), nucleotide 1037-5161 encodes Cas9 protein, nucleotide 5162-5209 encodes Nuclear Localization Signal (NLS), nucleotide 5219-5266 encodes Nuclear Localization Signal (NLS), nucleotide 5276-5332 encodes polypeptide P2A (amino acid sequence of polypeptide P2A is "ATNFSLLKQAGDVEENPGP", cleavage position is between first amino acid residue and second amino acid residue from C-terminal), nucleotides 5333-6046 encode EGFP protein, nucleotides 6056-6109 encode polypeptide T2A (the amino acid sequence of polypeptide T2A is EGRGSLLTCGDVEENPGP, the cleavage position is between the first amino acid residue and the second amino acid residue from the C terminal), nucleotides 6110-6703 encode Puromycin protein (Puro protein for short), nucleotides 6722-7310 constitute WPRE sequence elements, nucleotides 7382-7615 constitute 3' LTR sequence elements, and nucleotides 7647-7871 constitute bGH poly (A) signal sequence elements. SEQ ID NO in patent application 202010084343.6: 2, the 911-6706 nucleotides form a fusion gene, and express a fusion protein. Due to the presence of self-cleaving polypeptide P2A and self-cleaving polypeptide T2A, the fusion protein spontaneously forms three proteins: proteins with Cas9 protein, proteins with EGFP protein, and proteins with Puro protein.
The pKG-U6gRNA vector, i.e., plasmid pKG-U6gRNA, is a circular plasmid, as set forth in SEQ ID NO: 3. SEQ ID NO in patent application 202010084343.6: 3, nucleotides 2280 to 2539 constitute the hU6 promoter and nucleotides 2558 to 2637 are used for transcription to form the gRNA backbone. When in use, a DNA molecule of about 20bp (target sequence binding region for transcription to form gRNA) is inserted into plasmid pKG-U6gRNA to form a recombinant plasmid, and the recombinant plasmid is transcribed in cells to obtain gRNA.
EXAMPLE 1 preparation of COL2A1 Gene knockout Bama pig monoclonal cell clone
Two high efficiency gRNA targets (COL 2A1-E27-gRNA3 target and COL2A1-E27-gRNA4 target) were selected from example 2.
The NCN protein was provided from the NCN protein solution prepared in example 3.
1. Preparation of gRNA
1. Preparation of COL2A1-T7-gRNA3 transcription template and COL2A1-T7-gRNA4 transcription template
COL2A1-T7-gRNA3 transcription template is a double-stranded DNA molecule, such as SEQ ID NO: 14.
COL2A1-T7-gRNA4 transcription template is a double-stranded DNA molecule, such as SEQ ID NO: 15.
2. In vitro transcription to obtain gRNA
COL2A1-T7-gRNA3 transcription template was used, in vitro transcription was performed using a trans Aid T7 High Yield Transcription Kit (Fermentas, K0441), followed by MEGA clear TM Transcription Clean-Up Kit (Thermo, AM 1908) was recovered and purified to give COL2A1-gRNA3.COL2A1-gRNA3 is single-stranded RNA, as shown in SEQ ID NO: shown at 16.
COL2A1-T7-gRNA4 transcription template was used, in vitro transcription was performed using a trans Aid T7 High Yield Transcription Kit (Fermentas, K0441), followed by MEGA clear TM Transcription Clean-Up Kit (Thermo, AM 1908) was recovered and purified to give COL2A1-gRNA4.COL2A1-gRNA4 is single-stranded RNA, as shown in SEQ ID NO: shown at 17.
COL2A1-gRNA3(SEQ ID NO:16):
GGCCAGGGAAACCCAUGACACCGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUCOL2A1-gRNA4(SEQ ID NO:17):
GGCCAGGGCGACCAUCUUCACCGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU
2. Transfection of porcine primary fibroblasts
1. COL2A1-gRNA3, COL2A1-gRNA4 and NCN proteins were co-transfected into porcine primary fibroblasts. Proportioning: about 10 ten thousand porcine primary fibroblasts: 1 μg COL2A1-gRNA3:1 μg COL2A1-gRNA4:4 μg NCN protein. Co-transfection was performed by electric shock transfection using a mammalian nuclear transfection kit (Neon kit, thermofiser) and a Neon TM transfection system electrotransfection apparatus (parameters set to 1450V, 10ms, 3 pulses).
2. After the step 1 is completed, the culture is carried out for 16 to 18 hours by adopting the complete culture solution, and then the culture is carried out by replacing the new complete culture solution. The total incubation time after electrotransformation was 48 hours.
3. After completion of step 2, the cells were digested with trypsin and collected, then washed with complete medium, then resuspended with complete medium, and then each individual monoclonal was individually picked and transferred to 96-well plates (1 cell per well, 100 μl of complete medium per well) and cultured for 2 weeks (new complete medium was changed every 2-3 days).
4. After completion of step 3, cells were digested with trypsin and collected (about 2/3 of the resulting cells per well were inoculated into 6-well plates filled with complete culture medium, and the remaining 1/3 were collected in 1.5mL centrifuge tubes).
5. The 6-well plate of step 4 was used to culture until the cells grew to 80% confluence, the cells were digested with trypsin and collected, and the cells were frozen using cell frozen stock (90% complete medium+10% dmso, volume ratio).
6. Taking the centrifuge tube in the step 4, taking cells, performing cell lysis, extracting genome DNA, performing PCR amplification by adopting a primer pair consisting of COL2A1-E27-JDF219 and COL2A1-E27-JDR660, and then performing electrophoresis. Porcine primary fibroblasts were used as wild-type control (WT).
7. After step 6 is completed, the PCR amplification product is recovered and sequenced.
The sequencing result of the primary fibroblast cells of pigs only has one, and the genotype of the primary fibroblast cells is wild type (also called homozygous wild type). If there are two types of sequencing results of a single cell clone, one is consistent with the sequencing results of the primary fibroblast of the pig, the other is mutated (the mutation comprises deletion, insertion or substitution of one or more nucleotides) compared with the sequencing results of the primary fibroblast of the pig, and the genotype of the single cell clone is heterozygous; if the sequencing result of a single cell clone is two, the single cell clone has mutation (the mutation comprises deletion, insertion or replacement of one or more nucleotides) compared with the sequencing result of a primary fibroblast of a pig, and the genotype of the single cell clone is a double-allele different mutant type; if the sequencing result of a single cell clone is one and a mutation (mutation includes deletion, insertion or substitution of one or more nucleotides) is made compared with the sequencing result of a primary fibroblast of a pig, the genotype of the single cell clone is the same mutant type of double alleles; if the sequencing result of a single cell clone is one and is consistent with the sequencing result of porcine primary fibroblasts, the genotype of the single cell clone is wild type (also referred to as homozygous wild type).
The results are shown in Table 1. The genotype of the single cell clone numbered 33 was wild type. The genotypes of the single cell clones numbered 4, 10, 14, 20, 21, 22 were heterozygous. The genotypes of the single cell clones numbered 1, 3, 5, 6, 7, 9, 11, 12, 13, 15, 16, 18, 19, 24, 25, 26, 28, 29, 30, 31, 32, 34, 35 were double allelic different mutants. The genotypes of the single cell clones numbered 2, 8, 17, 23, 27 were identical mutants of the double alleles. The rate of obtaining COL2A1 gene-editing single-cell clones was 97.1%.
Exemplary sequencing alignment results are shown in FIGS. 1-4. FIG. 1 shows the result of the forward sequencing of the single cell clone No. 33 aligned with the wild type sequence, and the result is determined to be wild type. FIG. 2 shows the result of the reverse sequencing of the single cell clone No. 14 aligned with the wild type sequence, and the result is judged as heterozygous. FIG. 3 shows the results of reverse sequencing of the single cell clone numbered 24 and the comparison of the wild type sequence, as a double allele variant. FIG. 4 shows the results of the forward sequencing of the single cell clone numbered 2 compared with the wild type sequence, which is a double allele identical mutant.
TABLE 1 genotype determination results for COL2A1 Gene editing Single cell clones
The single cell clones of the same mutant type and different mutant types of the double alleles are all target single cell clones. And (3) taking the cells as nuclear transfer donor cells to clone somatic cells, so that cloned pigs can be obtained, namely type II collagenosis model pigs.
Example 2 selection of efficient gRNA targets for COL2A1 Gene
Pig COL2A1 gene information: encoding type ii collagen α1 chain; chromosome 5; gene ID 397323,Sus scrofa. The protein encoded by the porcine COL2A1 gene is shown as XP_020948270.1 (13-MAY-2017) in NCBI. The partial segment of the protein coded by the pig COL2A1 gene is shown as SEQ ID NO: shown at 8. In the pig genome DNA, the COL2A1 gene shares 54 exons, the 27 th coding exon and 300bp of each of the upstream and downstream are shown in SEQ ID NO: shown at 9.
1. Conservation analysis of COL2A1 gene preset deletion region and adjacent genome sequence
10 primary Bama pigs, 6 females (named BC1, BC2, BC3, BC4, BC5, BC6, respectively) and 4 males (named BX1, BX2, BX3, BX4, respectively).
COL2A1-E27-JDF220:CTGTGCCCTTCCACAGTAGG;
COL2A1-E27-JDR660:GGCTAAAGCCGAGTATCCCC;
COL2A1-E27-JDF219:CCTGTGCCCTTCCACAGTAG;
COL2A1-E27-JDR633:CTGCCCCATGGAAGACTGTT。
Genomic DNA extracted from porcine ear tissue designated BX4 was used as a template for PCR amplification using different primer pairs, followed by 1% agarose gel electrophoresis. The electrophoresis pattern is shown in FIG. 5. In fig. 5: group 1: a primer pair consisting of COL2A1-E27-JDF219 and COL2A1-E27-JDR633 is adopted; group 2: a primer pair consisting of COL2A1-E27-JDF219 and COL2A1-E27-JDR660 is adopted; group 3: a primer pair consisting of COL2A1-E27-JDF220 and COL2A1-E27-JDR633 is adopted; group 4: a primer pair consisting of COL2A1-E27-JDF220 and COL2A1-E27-JDR660 was used. As a result, it was found that the target fragment was amplified preferably using a primer set consisting of COL2A1-E27-JDF219 and COL2A1-E27-JDR 660.
PCR amplification was performed using 10 pig genomic DNAs as templates, respectively, using primer pairs consisting of COL2A1-E27-JDF219 and COL2A1-E27-JDR660, followed by 1% agarose gel electrophoresis. The electrophoresis pattern is shown in FIG. 6. And (3) recovering PCR amplification products, sequencing, and comparing the sequencing results with COL2A1 gene sequences in a public database for analysis. The conserved regions common to 10 pigs were selected for the design of the gRNA targets.
2. Screening target
A plurality of targets are initially screened by screening NGG (avoiding possible mutation sites), and 4 targets are further screened from the targets through preliminary experiments.
The 4 targets were as follows:
COL2A1-E27-gRNA1 target: TGGACCTCCAGGTCCCCAAG;
COL2A1-E27-gRNA2 target: CGAGCCCCTTGGGGACCTGG;
COL2A1-E27-gRNA3 target: CCAGGGAAACCCATGACACC;
COL2A1-E27-gRNA4 target: CCAGGGCGACCATCTTCACC.
3. Preparation of gRNA
Plasmid pKG-U6gRNA was taken and digested with restriction enzyme BbsI, and the vector backbone (about 3kb linear fragment) was recovered.
COL2A1-E27-gRNA1-S and COL2A1-E27-gRNA1-A were synthesized, respectively, and then mixed and annealed to give double-stranded DNA molecules having cohesive ends. The double-stranded DNA molecule having a cohesive end was ligated to the vector backbone to obtain plasmid pKG-U6gRNA (COL 2A1-E27-gRNA 1). Plasmid pKG-U6gRNA (COL 2A1-E27-gRNA 1) expresses the sequence of SEQ ID NO:10, sgRNA shown in FIG. 10 COL2A1-E27-gRNA1 。
sgRNA COL2A1-E27-gRNA1 (SEQ ID NO:10):
UGGACCUCCAGGUCCCCAAGguuuuagagcuagaaauagcaaguuaaaauaaggcuaguccguuaucaacuugaaaaaguggcaccgagucggugcuuuu
COL2A1-E27-gRNA2-S and COL2A1-E27-gRNA2-A were synthesized separately, and then mixed and annealed to give double-stranded DNA molecules having cohesive ends. The double-stranded DNA molecule having a cohesive end was ligated to the vector backbone to obtain plasmid pKG-U6gRNA (COL 2A1-E27-gRNA 2). Plasmid pKG-U6gRNA (COL 2A1-E27-gRNA 2) expresses the sequence of SEQ ID NO:11, sgRNA shown in FIG. 11 COL2A1-E27-gRNA2 。
sgRNA COL2A1-E27-gRNA2 (SEQ ID NO:11):
CGAGCCCCUUGGGGACCUGGguuuuagagcuagaaauagcaaguuaaaauaaggcuaguccguuaucaacuugaaaaaguggcaccgagucggugcuuuu
COL2A1-E27-gRNA3-S and COL2A1-E27-gRNA3-A were synthesized separately, and then mixed and annealed to give double-stranded DNA molecules having cohesive ends. The double-stranded DNA molecule having a cohesive end was ligated to the vector backbone to obtain plasmid pKG-U6gRNA (COL 2A1-E27-gRNA 3). Plasmid pKG-U6gRNA (COL 2A1-E27-gRNA 3) expresses the sequence of SEQ ID NO:12, sgRNA shown in FIG. 12 COL2A1-E27-gRNA3 。
sgRNA COL2A1-E27-gRNA3 (SEQ ID NO:12):
CCAGGGAAACCCAUGACACCguuuuagagcuagaaauagcaaguuaaaauaaggcuaguccguuaucaacuugaaaaaguggcaccgagucggugcuuuu
Synthesis of COL2A1-E27-gR, respectivelyNA4-S and COL2A1-E27-gRNA4-A are then mixed and annealed to give a double stranded DNA molecule with cohesive ends. The double-stranded DNA molecule having a cohesive end was ligated to the vector backbone to obtain plasmid pKG-U6gRNA (COL 2A1-E27-gRNA 4). Plasmid pKG-U6gRNA (COL 2A1-E27-gRNA 4) expresses the sequence of SEQ ID NO:13, sgRNA shown in FIG. 13 COL2A1-E27-gRNA4 。
sgRNA COL2A1-E27-gRNA4 (SEQ ID NO:13):
CCAGGGCGACCAUCUUCACCguuuuagagcuagaaauagcaaguuaaaauaaggcuaguccguuaucaacuugaaaaaguggcaccgagucggugcuuuu
COL2A1-E27-gRNA1-S:caccgTGGACCTCCAGGTCCCCAAG;
COL2A1-E27-gRNA1-A:aaacCTTGGGGACCTGGAGGTCCAc;
COL2A1-E27-gRNA2-S:caccgCGAGCCCCTTGGGGACCTGG;
COL2A1-E27-gRNA2-A:aaacCCAGGTCCCCAAGGGGCTCGc;
COL2A1-E27-gRNA3-S:caccgCCAGGGAAACCCATGACACC;
COL2A1-E27-gRNA3-A:aaacGGTGTCATGGGTTTCCCTGGc;
COL2A1-E27-gRNA4-S:caccgCCAGGGCGACCATCTTCACC;
COL2A1-E27-gRNA4-A:aaacGGTGAAGATGGTCGCCCTGGc。
COL2A1-E27-gRNA1-S, COL A1-E27-gRNA1-A, COL A1-E27-gRNA2-S, COL A1-E27-gRNA2-A, COL A1-E27-gRNA3-S, COL A1-E27-gRNA3-A, COL A1-E27-gRNA4-S, COL A1-E27-gRNA4-A are single stranded DNA molecules.
4. Editing efficiency comparison of different target combinations
1. Co-transfection
A first group: plasmid pKG-U6gRNA (COL 2A1-E27-gRNA 1) and plasmid pKG-GE3 were co-transfected into porcine primary fibroblasts. Proportioning: about 20 ten thousand porcine primary fibroblasts: 0.92. Mu.g of plasmid pKG-U6gRNA (COL 2A1-E27-gRNA 1): 1.08 μg of plasmid pKG-GE3.
Second group: plasmid pKG-U6gRNA (COL 2A1-E27-gRNA 2) and plasmid pKG-GE3 were co-transfected into porcine primary fibroblasts. Proportioning: about 20 ten thousand porcine primary fibroblasts: 0.92. Mu.g of plasmid pKG-U6gRNA (COL 2A1-E27-gRNA 2): 1.08 μg of plasmid pKG-GE3.
Third group: plasmid pKG-U6gRNA (COL 2A1-E27-gRNA 3) and plasmid pKG-GE3 were co-transfected into porcine primary fibroblasts. Proportioning: about 20 ten thousand porcine primary fibroblasts: 0.92. Mu.g of plasmid pKG-U6gRNA (COL 2A1-E27-gRNA 3): 1.08 μg of plasmid pKG-GE3.
Fourth group: plasmid pKG-U6gRNA (COL 2A1-E27-gRNA 4) and plasmid pKG-GE3 were co-transfected into porcine primary fibroblasts. Proportioning: about 20 ten thousand porcine primary fibroblasts: 0.92. Mu.g of plasmid pKG-U6gRNA (COL 2A1-E27-gRNA 4): 1.08 μg of plasmid pKG-GE3.
Fifth group: and (3) carrying out electrotransformation operation on the primary fibroblast of the pig without adding plasmid according to the same electrotransformation parameters.
Co-transfection was performed by electric shock transfection using a mammalian nuclear transfection kit (Neon kit, thermofiser) and a Neon TM transfection system electrotransfection apparatus (parameters set to 1450V, 10ms, 3 pulses).
2. After the step 1 is completed, the culture is carried out for 12 to 18 hours by adopting the complete culture solution, and then the culture is carried out by replacing the new complete culture solution. The total incubation time after electrotransformation was 48 hours.
3. After the completion of step 2, cells were digested and collected with trypsin, lysed, genomic DNA was extracted, PCR amplification was performed using a primer set consisting of COL2A1-E27-JDF219 and COL2A1-E27-JDR660, followed by 1% agarose gel electrophoresis. Detecting mutation condition of target genes of cells.
And cutting and recovering a target product, sending the target product to a sequencing company for sequencing, and analyzing a sequencing peak diagram of a sequencing result by using a webpage version synthetic ICE tool to obtain the gene editing efficiency of different targets. The gene editing efficiencies of the first group, the second group, the third group and the fourth group are sequentially 5%, 63%, 81% and 68%, and the fifth group is not subjected to gene editing. The results show that the COL2A1-E27-gRNA3 target and the COL2A1-E27-gRNA4 target have higher editing efficiency.
EXAMPLE 3 preparation and purification of NCN protein
1. Construction of prokaryotic Cas9 high-efficiency expression vector
The schematic structure of plasmid pET-32a is shown in FIG. 7.
Plasmid pKG-GE4 was obtained by transformation with plasmid pET-32a as starting plasmid. Plasmid pET32a-T7lac-phoA SP-TrxA-His-EK-NLS-spCas9-NLS-T7ter (abbreviated as plasmid pKG-GE 4), as shown in SEQ ID NO:1 is a circular plasmid, and the structure schematic diagram is shown in figure 8.
SEQ ID NO:1, nucleotides 5121 to 5139 constitute the T7 promoter, nucleotides 5140 to 5164 encode the Lac operator, nucleotides 5178 to 5201 constitute the Ribosome Binding Site (RBS), nucleotides 5209 to 5271 encode the alkaline phosphatase signal peptide (phoA signal peptide), nucleotides 5272 to 5598 encode the TrxA protein, and nucleotides 5620 to 5637 encode the His-Tag (also known as His) 6 Tag), nucleotide 5638-5652 encodes enterokinase cleavage site (EK cleavage site), nucleotide 5656-5670 encodes nuclear localization signal, nucleotide 5701-9801 encodes spCas9 protein, nucleotide 9802-9849 encodes nuclear localization signal, and nucleotide 9902-9949 constitutes T7 terminator. The nucleotides encoding spCas9 protein have been codon optimized for the e.coli BL21 (DE 3) strain.
The major modifications of plasmid pKG-GE4 were as follows: (1) the coding region of the TrxA protein is reserved, and the TrxA protein can help the expressed target protein to form disulfide bonds and increase the solubility and activity of the target protein; adding a coding sequence of an alkaline phosphatase signal peptide before the coding region of the TrxA protein, wherein the alkaline phosphatase signal peptide can guide the expressed target protein to be secreted into a periplasmic cavity of a membrane of bacteria and can be cleaved by a prokaryotic periplasmic signal peptidase; (2) adding a coding sequence of His-Tag after the coding sequence of TrxA protein, wherein the His-Tag can be used for enriching expressed target protein; (3) adding a coding sequence of enterokinase enzyme cutting site DDDDK (Asp-Asp-Asp-Asp-Lys) at the downstream of the coding sequence of His-Tag, and removing the His-Tag and the fused TrxA protein at the upstream under the action of enterokinase; (4) and inserting a Cas9 gene which is subjected to codon optimization and is suitable for escherichia coli BL21 (DE 3) strain expression, and simultaneously adding a nuclear localization signal coding sequence at the upstream and downstream of the gene, so as to increase the nuclear localization capability of the Cas9 protein purified at a later stage.
The fusion gene in the plasmid pKG-GE4 is shown as SEQ ID NO:1, nucleotide numbers 5209-9852, encoding SEQ ID NO:2 (fusion protein TrxA-His-EK-NLS-spCas9-NLS, abbreviated as PRONCN protein). Due to the presence of the alkaline phosphatase signal peptide and the enterokinase cleavage site, the fusion protein is cleaved by enterokinase to form the sequence of SEQ ID NO:3, the protein shown in SEQ ID NO:3 is designated NCN protein.
2. Induction of expression
1. The plasmid pKG-GE4 was introduced into E.coli BL21 (DE 3) to obtain a recombinant strain.
2. The recombinant bacteria obtained in step 1 were inoculated into liquid LB medium containing 100. Mu.g/ml ampicillin, and cultured overnight at 37℃under shaking at 200 rpm.
3. Inoculating the bacterial liquid obtained in the step 2 into a liquid LB culture medium, and culturing at 30 ℃ and 230rpm under shaking until OD 600nm Value = 1.0, isopropyl thiogalactoside (IPTG) was then added to a concentration of 0.5mM in the system, followed by shaking culture at 25 ℃, 230rpm for 12 hours, and centrifugation at 4 ℃, 10000g for 15 minutes, and the cells were collected.
4. And (3) washing the thalli obtained in the step (3) with PBS buffer solution.
3. Purification of fusion protein TrxA-His-EK-NLS-spCas9-NLS
1. And (3) adding the crude extraction buffer solution into the thalli obtained in the step (II) and suspending the thalli, crushing the thalli by using a homogenizer (1000 par circulation is performed three times), centrifuging at 4 ℃ and 15000g for 30min, collecting supernatant, filtering the supernatant by using a 0.22 mu m pore size filter membrane, and collecting filtrate. In this step, 10ml of the crude extraction buffer was mixed per g of the wet cells.
Crude extraction buffer: comprises 20mM Tris-HCl (pH 8.0), 0.5M NaCl, 5mM Imidazole, 1mM PMSF, the balance ddH 2 O。
2. The fusion protein was purified by affinity chromatography.
Firstly, balancing a Ni-NTA agarose column (the flow rate is 1 ml/min) by adopting balancing liquid with 5 column volumes; then 50ml of the filtrate obtained in the step 1 is loaded (the flow rate is 0.5-1 ml/min); the column was then washed with 5 column volumes of equilibration liquid (flow rate 1 ml/min); the column was then washed with 5 column volumes of buffer (flow rate 1 ml/min) to remove the contaminating proteins; then eluting with 10 column volumes of eluent at a flow rate of 0.5-1ml/min, and collecting the column-passing solution (90-100 ml).
Ni-NTA agarose column: gold Style, L00250/L00250-C, packing 10ml.
Balancing solution: containing 20mM Tris-HCl (pH 8.0), 0.5M NaCl, 5mM Imidazole, the balance ddH 2 O。
Buffer solution: containing 20mM Tris-HCl (pH 8.0), 0.5M NaCl, 50mM Imidazole, the balance ddH 2 O。
Eluent: containing 20mM Tris-HCl (pH 8.0), 0.5M NaCl, 500mM Imidazole, the balance ddH 2 O。
4. Cleavage of fusion protein TrxA-His-EK-NLS-spCas9-NLS and purification of NCN protein
1. 15ml of the post-column solution collected in step three was concentrated to 200. Mu.l using an Amicon ultrafiltration tube (Sigma, UFC9100, capacity 15 ml) and then diluted to 1ml with 25mM Tris-HCl (pH 8.0). 6 ultrafiltration tubes were used to give a total of 6ml.
2. With His of commercial origin 6 Tagged recombinant bovine enterokinase (organisms, C620031, recombinant bovine enterokinase light chain, his-bearing) 6 Tag Recombinant Bovine Enterokinase Light Chain, his) was added to the solution (about 6 ml) obtained in step 1 and digested at 25℃for 16 hours. 2 units of enterokinase were added in a ratio of 50. Mu.g protein.
3. The solution (about 6 ml) from step 2 was taken, mixed with 480. Mu.l of Ni-NTA resin (Kirsrui, L00250/L00250-C) and spun at room temperature for 15min, then centrifuged at 7000g for 3min, and the supernatant (4-5.5 ml) was collected.
4. The supernatant obtained in the step 3 was concentrated to 200. Mu.l using an Amicon ultrafiltration tube (Sigma, UFC9100, capacity: 15 ml), and then added to an enzyme stock solution to adjust the protein concentration to 5mg/ml, thereby obtaining an NCN protein solution.
The protein in NCN protein solution has 15 amino acid residues at the N end as shown in SEQ ID NO:3 from positions 1 to 15, i.e.NCN protein.
Enzyme stock solution (pH 7.4): contains 10mM Tris,300mM NaCl,0.1mM EDTA,1mM DTT,50% (volume ratio) of glycerin, the restIs ddH 2 O。
Example 4 Performance of NCN protein
The NCN protein was provided from the NCN protein solution prepared in example 3.
The selection of 2 gRNA targets targeting TTN genes was as follows:
TTN-gRNA1 target: AGAGCACAGTCAGCCTGGCG;
TTN-gRNA2 target: CTTCCAGAATTGGATCTCCG.
The primers used to identify the target fragment comprising the gRNA in the TTN gene were as follows:
TTN-F55:TACGGAATTGGGGAGCCAGCGGA;
TTN-R560:CAAAGTTAACTCTCTGTGTCT。
1. preparation of gRNA
1. Preparation of TTN-T7-gRNA1 transcription template and TTN-T7-gRNA2 transcription template
TTN-T7-gRNA1 transcription template is double-stranded DNA molecule, such as SEQ ID NO: 4.
TTN-T7-gRNA2 transcription template is double-stranded DNA molecule, such as SEQ ID NO: shown at 5.
2. In vitro transcription to obtain gRNA
TTN-T7-gRNA1 transcription template is adopted, trans-air T7 High Yield Transcription Kit (Fermentas, K0441) is adopted for in vitro transcription, and then MEGA clear is adopted TM Transcription Clean-Up Kit (Thermo, AM 1908) was recovered and purified to obtain TTN-gRNA1.TTN-gRNA1 is a single-stranded RNA, as set forth in SEQ ID NO: shown at 6.
TTN-T7-gRNA2 transcription template is adopted, trans-air T7 High Yield Transcription Kit (Fermentas, K0441) is adopted for in vitro transcription, and then MEGA clear is adopted TM Transcription Clean-Up Kit (Thermo, AM 1908) was recovered and purified to obtain TTN-gRNA2.TTN-gRNA2 is a single-stranded RNA, as set forth in SEQ ID NO: shown at 7.
2. Optimization of dosage proportion of gRNA and NCN proteins
1. Co-transfected porcine primary fibroblasts
A first group: the TTN-gRNA1, TTN-gRNA2 and NCN proteins were co-transfected into porcine primary fibroblasts. Proportioning: about 10 ten thousand porcine primary fibroblasts: 0.5 μg TTN-gRNA1:0.5 μg TTN-gRNA2:4 μg NCN protein.
Second group: the TTN-gRNA1, TTN-gRNA2 and NCN proteins were co-transfected into porcine primary fibroblasts. Proportioning: about 10 ten thousand porcine primary fibroblasts: 0.75 μg TTN-gRNA1:0.75 μg TTN-gRNA2:4 μg NCN protein.
Third group: the TTN-gRNA1, TTN-gRNA2 and NCN proteins were co-transfected into porcine primary fibroblasts. Proportioning: about 10 ten thousand porcine primary fibroblasts: 1 μg TTN-gRNA1:1 μg TTN-gRNA2:4 μg NCN protein.
Fourth group: the TTN-gRNA1, TTN-gRNA2 and NCN proteins were co-transfected into porcine primary fibroblasts. Proportioning: about 10 ten thousand porcine primary fibroblasts: 1.25 μg TTN-gRNA1:1.25 μg TTN-gRNA2:4 μg NCN protein.
Fifth group: TTN-gRNA1 and TTN-gRNA2 were co-transfected into porcine primary fibroblasts. Proportioning: about 10 ten thousand porcine primary fibroblasts: 1 μg TTN-gRNA1:1 μg TTN-gRNA2.
Co-transfection was performed by electric shock transfection using a mammalian nuclear transfection kit (Neon kit, thermofiser) and a Neon TM transfection system electrotransfection apparatus (parameters set to 1450V, 10ms, 3 pulses).
2. After the step 1 is completed, the culture is carried out for 12 to 18 hours by adopting the complete culture solution, and then the culture is carried out by replacing the new complete culture solution. The total incubation time after electrotransformation was 48 hours.
3. After the step 2 is completed, cells are digested and collected by trypsin, genomic DNA is extracted, PCR amplification is performed by using a primer pair consisting of TTN-F55 and TTN-R560, and then 1% agarose gel electrophoresis is performed.
The electrophoresis pattern is shown in FIG. 9. The 505bp band is wild type band (WT), and the 254bp band (about 251bp of the 505bp theoretical deletion of the wild type band) is deletion mutation band (MT).
Gene deletion mutation efficiency = (MT gray scale/MT band bp number)/(WT gray scale/WT band bp number + MT gray scale/MT band bp number) ×100%. The first group of gene deletion mutation efficiency was 19.9%, the second group of gene deletion mutation efficiency was 39.9%, the third group of gene deletion mutation efficiency was 79.9%, and the fourth group of gene deletion mutation efficiency was 44.3%. The fifth group had no mutation.
The results show that when the mass ratio of two gRNAs to NCN protein is 1:1:4, the actual dosage is 1 mug: 1 μg: the 4 μg time base is most efficient for editing. Thus, the optimal amount of two grnas to NCN protein was determined to be 1 μg:1 μg:4 μg.
3. Comparison of Gene editing efficiency of NCN protein and commercial Cas9 protein
1. Co-transfected porcine primary fibroblasts
Cas9-a group: TTN-gRNA1, TTN-gRNA2 and commercial Cas9-a protein were co-transfected into porcine primary fibroblasts. Proportioning: about 10 ten thousand porcine primary fibroblasts: 1 μg TTN-gRNA1:1 μg TTN-gRNA2:4 μg Cas9-a protein.
pKG-GE4 group: the TTN-gRNA1, TTN-gRNA2 and NCN proteins were co-transfected into porcine primary fibroblasts. Proportioning: about 10 ten thousand porcine primary fibroblasts: 1 μg TTN-gRNA1:1 μg TTN-gRNA2:4 μg NCN protein.
Cas9-B group: TTN-gRNA1, TTN-gRNA2 and commercial Cas9-B protein were co-transfected into porcine primary fibroblasts. Proportioning: about 10 ten thousand porcine primary fibroblasts: 1 μg TTN-gRNA1:1 μg TTN-gRNA2:4 μg Cas9-B protein.
Control group: TTN-gRNA1, TTN-gRNA2 were co-transfected into porcine primary fibroblasts. Proportioning: about 10 ten thousand porcine primary fibroblasts: 1 μg TTN-gRNA1:1 μg TTN-gRNA2.
Co-transfection was performed by electric shock transfection using a mammalian nuclear transfection kit (Neon kit, thermofiser) and a Neon TM transfection system electrotransfection apparatus (parameters set to 1450V, 10ms, 3 pulses).
2. After the step 1 is completed, the culture is carried out for 12 to 18 hours by adopting the complete culture solution, and then the culture is carried out by replacing the new complete culture solution. The total incubation time after electrotransformation was 48 hours.
3. After the step 2 is completed, cells are digested and collected by trypsin, genomic DNA is extracted, PCR amplification is performed by using a primer pair consisting of TTN-F55 and TTN-R560, and then 1% agarose gel electrophoresis is performed.
The electrophoresis pattern is shown in FIG. 10. The gene deletion mutation efficiency of the commercial Cas9-A protein is 28.5%, the gene deletion mutation efficiency of the NCN protein is 85.6%, and the gene deletion mutation efficiency of the commercial Cas9-B protein is 16.6%.
The results show that compared with the commercial Cas9 protein, the NCN protein prepared by the method provided by the invention has the advantage that the gene editing efficiency is obviously improved.
The present invention is described in detail above. It will be apparent to those skilled in the art that the present invention can be practiced in a wide range of equivalent parameters, concentrations, and conditions without departing from the spirit and scope of the invention and without undue experimentation. While the invention has been described with respect to specific embodiments, it will be appreciated that the invention may be further modified. In general, this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains. The application of some of the basic features may be done in accordance with the scope of the claims that follow.
Claims (13)
- Application of COL2A1-gRNA3, COL2A1-gRNA4 and NCN proteins in preparation of a kit;the COL2A1-gRNA3 is sgRNA, and the target sequence binding region is shown in SEQ ID NO:16 from nucleotide 3 to nucleotide 22; the COL2A1-gRNA4 is sgRNA, and the target sequence binding region is shown in SEQ ID NO:17 from nucleotide 3 to nucleotide 22; the NCN protein is a Cas9 protein or a fusion protein with the Cas9 protein;the kit is used as follows (a) or (b) or (c): (a) preparing recombinant porcine cells; (b) preparing a model pig of type ii collagen disease; (c) Preparing a type II collagenosis cell model, a type II collagenosis tissue model or a type II collagenosis organ model.
- Application of COL2A1-gRNA3, COL2A1-gRNA4 and PRONCN proteins in preparation of a kit;COL2A1-gRNA3 is COL2A1-gRNA3 as defined in claim 1;COL2A1-gRNA4 is COL2A1-gRNA4 as described in claim 1;the PRONCN protein comprises the following elements from upstream to downstream: signal peptide, chaperone protein, protein tag, protease cleavage site, nuclear localization signal, cas9 protein, nuclear localization signal;the kit is used as follows (a) or (b) or (c): (a) preparing recombinant porcine cells; (b) preparing a model pig of type ii collagen disease; (c) Preparing a type II collagenosis cell model, a type II collagenosis tissue model or a type II collagenosis organ model.
- Application of COL2A1-gRNA3, COL2A1-gRNA4 and specific plasmids in preparation of a kit;COL2A1-gRNA3 is COL2A1-gRNA3 as defined in claim 1;COL2A1-gRNA4 is COL2A1-gRNA4 as described in claim 1;the specific plasmid comprises the following elements from upstream to downstream: a promoter, an operator, a ribosome binding site, a gene encoding a procn protein, and a terminator; the PRONCN protein comprises the following elements from upstream to downstream: signal peptide, chaperone protein, protein tag, protease cleavage site, nuclear localization signal, cas9 protein, nuclear localization signal;the kit is used as follows (a) or (b) or (c): (a) preparing recombinant porcine cells; (b) preparing a model pig of type ii collagen disease; (c) Preparing a type II collagenosis cell model, a type II collagenosis tissue model or a type II collagenosis organ model.
- 4. A kit comprising COL2A1-gRNA3, COL2A1-gRNA4 and NCN protein;COL2A1-gRNA3 is COL2A1-gRNA3 as defined in claim 1; COL2A1-gRNA4 is COL2A1-gRNA4 as described in claim 1; the NCN protein is the NCN protein of claim 1;the kit is used as follows (a) or (b) or (c): (a) preparing recombinant porcine cells; (b) preparing a model pig of type ii collagen disease; (c) Preparing a type II collagenosis cell model, a type II collagenosis tissue model or a type II collagenosis organ model.
- 5. A kit comprising COL2A1-gRNA3, COL2A1-gRNA4 and procn proteins;COL2A1-gRNA3 is COL2A1-gRNA3 as defined in claim 1; COL2A1-gRNA4 is COL2A1-gRNA4 as described in claim 1; the proccn protein of claim 2;the kit is used as follows (a) or (b) or (c): (a) preparing recombinant porcine cells; (b) preparing a model pig of type ii collagen disease; (c) Preparing a type II collagenosis cell model, a type II collagenosis tissue model or a type II collagenosis organ model.
- 6. A kit comprising COL2A1-gRNA3, COL2A1-gRNA4 and a specific plasmid;COL2A1-gRNA3 is COL2A1-gRNA3 as defined in claim 1; COL2A1-gRNA4 is COL2A1-gRNA4 as described in claim 1; a specific plasmid as defined in claim 3;the kit is used as follows (a) or (b) or (c): (a) preparing recombinant porcine cells; (b) preparing a model pig of type ii collagen disease; (c) Preparing a type II collagenosis cell model, a type II collagenosis tissue model or a type II collagenosis organ model.
- 7. A method of preparing a recombinant porcine cell comprising the steps of: co-transfecting COL2A1-gRNA3, COL2A1-gRNA4 and NCN proteins into a pig cell to obtain a recombinant pig cell; COL2A1-gRNA3 is COL2A1-gRNA3 as defined in claim 1; COL2A1-gRNA4 is COL2A1-gRNA4 as described in claim 1; the NCN protein according to claim 1.
- 8. The use according to claim 1 or the kit according to claim 4 or the method according to claim 7, characterized in that: the NCN protein is shown as SEQ ID NO: 3.
- 9. The use or kit or method according to claim 8, wherein:the preparation method of the NCN protein comprises the following steps:(1) Introducing plasmid pKG-GE4 into escherichia coli BL21 (DE 3) to obtain recombinant bacteria;(2) Culturing the recombinant bacteria at 30 ℃ by adopting a liquid culture medium, then adding IPTG and performing induction culture at 25 ℃, and then collecting thalli;(3) Crushing the collected thalli, and collecting a crude protein solution;(4) Purification of His-bearing proteins from the crude protein solution by affinity chromatography 6 A tagged fusion protein;(5) By using a composition having His 6 Enterokinase cleavage of tag with His 6 Tagged fusion proteins are then removed with Ni-NTA resin to remove His 6 A tagged protein, resulting in a purified NCN protein;plasmid pKG-GE4 has the sequence of SEQ ID NO:1 from nucleotide 5209 to nucleotide 9852.
- 10. A recombinant porcine cell produced by the method of claim 7 or 8 or 9.
- 11. Use of the recombinant porcine cell of claim 10 for the preparation of a model pig for type ii collagen disease.
- 12. A porcine tissue, organ or cell of a type ii collagen disease model pig prepared using the recombinant porcine cell of claim 10.
- 13. Use of a recombinant porcine cell of claim 10, a porcine tissue of claim 12, a porcine organ of claim 12, a porcine cell of claim 12 or a model porcine of type ii collagen disease prepared using a recombinant porcine cell of claim 10 as follows (d 1) or (d 2) or (d 3) or (d 4):(d1) Screening a medicament for treating type II collagen diseases;(d2) Performing drug effect evaluation of the type II collagen disease drug;(d3) Performing therapeutic effect evaluation of gene therapy and/or cell therapy of type II collagen diseases;(d4) The pathogenesis of type II collagen diseases is studied.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211031148.2A CN116103339A (en) | 2022-08-26 | 2022-08-26 | Kit and application thereof in construction of pig nuclear transfer donor cells of COL2A1 gene mutation type II collagen disease model |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211031148.2A CN116103339A (en) | 2022-08-26 | 2022-08-26 | Kit and application thereof in construction of pig nuclear transfer donor cells of COL2A1 gene mutation type II collagen disease model |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116103339A true CN116103339A (en) | 2023-05-12 |
Family
ID=86254963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211031148.2A Pending CN116103339A (en) | 2022-08-26 | 2022-08-26 | Kit and application thereof in construction of pig nuclear transfer donor cells of COL2A1 gene mutation type II collagen disease model |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116103339A (en) |
-
2022
- 2022-08-26 CN CN202211031148.2A patent/CN116103339A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104846011A (en) | Method for synthesizing royal jelly main protein 1 by using bombyx mori posterior silkgland | |
CN114231533B (en) | Preparation method of miniature pig with human complement regulatory protein knocked in at Rosa26 site by fixed point | |
CN113278618B (en) | gRNA for specifically recognizing porcine COL1A1 gene, and biological material, kit and application thereof | |
CN111575319B (en) | Efficient CRISPR RNP and donor DNA co-location mediated gene insertion or replacement method and application thereof | |
CN112094868B (en) | Method for preparing CD163 gene edited pig by using single base editor SpRY-BE4 | |
CN115927320A (en) | Application of gene editing system in preparation of SLC13A1 gene mutation hyposulfatemia model pig nuclear transplantation donor cells | |
CN111549070B (en) | Method for editing X chromosome multicopy gene to realize animal sex control | |
WO2021042470A1 (en) | Use of combination of grna targets in constructing cell lines of porcine models of haemophilia a, b and ab | |
CN116103339A (en) | Kit and application thereof in construction of pig nuclear transfer donor cells of COL2A1 gene mutation type II collagen disease model | |
CN116064523A (en) | Gene editing system and application thereof in construction of HPS1 gene mutation sea PRS model pig nuclear transfer donor cells | |
CN116004715A (en) | Application of gene editing system in preparation of SMN1 gene mutation spinal muscular atrophy model pig nuclear transfer donor cells | |
CN116064524A (en) | Application of gene editing system in construction of CFTR gene mutation cystic fibrosis model pig nuclear transfer donor cells | |
CN116064473A (en) | Kit for constructing ataxia-telangiectasia model pig nuclear transfer donor cells with ATM gene mutation | |
CN116064683A (en) | Gene editing system and application thereof in preparation of arrhythmia model pig nuclear transfer donor cells with SCN5A gene mutation | |
CN116064661A (en) | Gene editing system for constructing NF1 gene mutation type I neurofibromatosis model pig nuclear transplantation donor cell and application thereof | |
CN112094866B (en) | Method for preparing CD163 gene editing pig by using SpRY-Cas9 system | |
CN115807036A (en) | Method for preparing BRCA2 gene mutation breast cancer model pig nuclear transplantation donor cell and special gene editing system thereof | |
CN115806981A (en) | Gene editing system and application thereof in construction of TNIP1 gene mutation psoriasis model pig nuclear transplantation donor cell | |
CN115976017A (en) | Gene editing system for constructing pig nuclear transplantation donor cells of SPR gene mutation type sepiapterin reductase deficiency model and application thereof | |
CN115927314A (en) | Gene editing system for constructing BRCA1 gene mutation breast cancer model pig nuclear transplantation donor cells and application thereof | |
CN116179543A (en) | CRISPR-specific targeting pig Cavin-1 gene-based sgRNA and application thereof | |
CN115927315A (en) | Gene editing system for constructing ZMPST 24 gene mutation type porcine nuclear transfer donor cell for premature senility syndrome model and application thereof | |
CN115786395A (en) | Gene editing system for constructing Huntington's chorea model pig nuclear transplantation donor cell with HTT gene mutation and application thereof | |
CN115927193A (en) | Method for preparing pure hair and toenail type ectodermal dysplasia model pig nuclear transplantation donor cell and special gene editing system thereof | |
CN115927456A (en) | Gene editing system for constructing pig nuclear transplantation donor cells of PAH (platelet activating factor) gene mutant phenylketonuria model and application of gene editing system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |